Deucravacitinib Dosage

Medically reviewed by Drugs.com. Last updated on Nov 19, 2024.

Usual Adult Dose for Plaque Psoriasis

6 mg orally once a day

Comments:

• Limitations of use: This drug is not recommended for use in combination with other potent immunosuppressants.
• Prior to treatment initiation, patients should be evaluated for latent or active tuberculosis infection.
• The use of live vaccines during therapy with this drug is not advised.

Use: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

Renal Dose Adjustments

No dose adjustment recommended

Liver Dose Adjustments

Mild or moderate liver dysfunction (Child-Pugh Class A or B): No adjustment recommended
Severe liver dysfunction (Child-Pugh Class C): Not recommended

Precautions

CONTRAINDICATIONS:

• History of hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

ESRD on dialysis: No adjustment recommended

Comments:

• This drug is not substantially cleared from systemic circulation by dialysis.

Other Comments

Administration advice:

• This drug may be taken with or without food.
• Do not cut, crush, or chew tablets.

Storage requirements:

• Store at 20C to 25C (68F to 77F).
• Excursions permitted between 15C and 30C (59F and 86F).

General:

• Before starting therapy, consider completing all age-appropriate vaccinations in accordance with immunization guidelines, including prophylactic herpes zoster vaccination.
• It is recommended to treat cases of active or latent tuberculosis prior to starting treatment with this drug.

Monitoring:

• Hepatic: Liver enzymes in patients with known or suspected liver disease (at baseline, and then periodically)
• Infections/Infestations: For signs and symptoms of infection, including viral reactivation and tuberculosis (before and during therapy)
• Metabolic: Serum triglycerides (periodically to monitor for elevations or hyperlipidemia)

Patient advice:

• Read the US FDA-approved patient labeling (Medication Guide).
• Inform health care provider of any prior cancer history.
• Report any symptoms of muscle pain or weakness.
• Promptly report signs and symptoms of infection to a health care provider.
• Discontinue this drug and seek immediate medical attention if any symptoms of serious hypersensitivity reactions occur.
• Avoid live vaccinations while on therapy.
• Understand the potential risks related to treatment with Janus kinase inhibitors.

Frequently asked questions

• Sotyktu vs Otezla: How do they compare?
• How long can I take Sotyktu for?
• How is Sotyktu given / administered?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer